In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...

In this rapidly evolving setting, clinicians are weighing the alleged harm of continuing these medications in patients for whom ACE inhibitors and ARBs have known benefit against the harm to their ...

In a study, patients who experienced hyperkalemia while on a renin-angiotensin-aldosterone-system inhibitor had the lowest 1-year risk of recurrent hyperkalemia when the medication was discontinued.

A multi-center study of more than 3,000 people with high blood pressure and brain aneurysms found that the use of RAAS inhibitors, a class of blood pressure lowering medications, reduced the risk of ...

Testing for aldosterone levels may hold the key to treatment-resistant hypertension and many other cardiac conditions, but what is the optimal approach to regulating this hormone?

Please provide your email address to receive an email when new articles are posted on . Many international medical societies have endorsed the continuation of renin-angiotensin-aldosterone system ...

At one time, dual RAAS blockade was expected to provide more-complete inhibition of RAAS among patients with DKD. Results of large clinical trials dashed these hopes, finding increased risk of AKI and ...

Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...

Studies in animals have shown that ACE2 is used by coronaviruses as a functional receptor. ARBs and ACE inhibitors increase the expression of ACE2; a hypothesis that their use may modify ...